Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment With Nivolumab and All-trans Retinoic Acid for Patients With Refractory Pancreatic Cancer

NCT05482451 is registered in ClinicalTrials.gov with China Medical University Hospital as lead sponsor.

NCT NCT05482451
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05482451 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment With Nivolumab and All-trans Retinoic Acid for Patients With Refractory Pancreatic Cancer
Lead sponsor
China Medical University Hospital
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 1, 2021
Completion date
February 28, 2025
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

effect of drug